ArticlePsoriasis (Auckland, N.Z.)2025

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.

Zeno Fratton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.